Business Context and Reporting Period
This Form 8-K was filed by Eyenovia, Inc. (not Hyperion Defi, Inc.) on December 21, 2018, reporting events occurring on December 19, 2018. The registrant is a Delaware corporation focused on ophthalmic drug development.
Key Financial Metrics and Transaction Details
- Transaction Type: Public offering of common stock via underwriting agreement with National Securities Corporation.
- Shares Issued: 1,200,000 shares initially, plus 180,000 shares via full exercise of the Over-Allotment Option (Total: 1,380,000 shares).
- Offering Price: $2.45 per share.
- Net Proceeds: Approximately $3.1 million after deducting underwriting discounts, commissions, and offering expenses.
- Closing Date: December 21, 2018.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, operating cash flow, margins, or debt levels as this is a current report regarding a capital raise, not a periodic financial statement.
Material Changes and Use of Proceeds
The primary material change is the increase in equity capital and cash liquidity resulting from the offering. The Company intends to use the net proceeds for the following purposes:
- Initiating Phase III clinical trials for its drug candidates, MicroPine and MicroProst.
- Completing formulation work for each development program.
- General corporate purposes, including working capital.
Guidance, Outlook, and Risks
Management Commentary: Management views the capital raise as essential to advancing the clinical development of its pipeline. The full exercise of the Over-Allotment Option indicates strong initial market demand.
Risks and Contingencies: The filing references customary representations, warranties, and indemnification provisions in the Underwriting Agreement. Success is contingent upon the successful execution of the Phase III trials and the ability to secure future funding if needed.
Key Facts for Investor Verification
- Verify the exact net proceeds received ($3.1 million) against the total shares sold (1,380,000) and the offering price ($2.45) to understand the effective underwriting discount.
- Confirm the specific timeline and milestones for the initiation of Phase III trials for MicroPine and MicroProst.
- Review the Company's existing cash balance prior to this offering to assess the total runway provided by the $3.1 million infusion.
- Check for any dilution impact on existing shareholders resulting from the issuance of 1,380,000 new shares.